In a clinical trial, researchers found that a drug called Daraxonrasib doubled the survival time in patients diagnosed with pancreatic cancer. This is significant as more than half of people with pancreatic cancer die within three months of diagnosis. Amid this, a report projected a shortfall of 100 million cancer care workers by 2050.


Report: Patients Who Took 'Daraxonrasib' Lived For 13.2 Months

New Drug Doubles Time In Patients With Pancreatic Cancer

A new personalised mRNA vaccine is offering fresh hope in the fight against pancreatic cancer—one of the hardest cancers to treat. In an early-stage trial, patients who responded to the vaccine showed long-term survival, with many living beyond six years after treatment. The vaccine is tailored to each patient following surgery, helping the immune system target cancer cells more effectively. While still in early stages, this approach could mark a major shift in how aggressive cancers are treated.


Pancreatic Cancer Breakthrough? Personalised mRNA Vaccine Shows Long-Term Survival In Early Trial